Clinical efficacy of interventional treatment combined with immunotherapy plus anti-angio-genesis targeted therapy in conversion therapy of advanced hepatocellular carcinoma
10.3760/cma.j.cn115610-20220909-00504
- VernacularTitle:介入联合免疫及抗血管生成靶向一线转化治疗晚期肝癌的临床疗效
- Author:
Zenan YUAN
1
;
Jianye CAI
;
Haibo LI
;
Zhenyu YU
;
Shuguang ZHU
;
Jianwen ZHANG
Author Information
1. 中山大学附属第三医院肝脏外科暨肝移植中心，广州 510630
- Keywords:
Liver neoplasms;
Advanced;
Immunotherapy;
Combined therapy;
Conver-sion therapy
- From:
Chinese Journal of Digestive Surgery
2022;21(S1):15-19
- CountryChina
- Language:Chinese
-
Abstract:
Targeted therapy is one of the conventional treatments for advanced hepato-cellular carcinoma (HCC). In recent years, immunotherapy has created a new era of HCC treatment. The combination of targeted therapy and immunotherapy has synergistic effects, which taking survival benefits to patients with advanced HCC. Local therapy, represented by interventional treatment, can rapidly control the development of tumor and promote the expression and releasing of tumor antigen. On the basis of local therapy and combination of immunotherapy plus targeted therapy, it can offer the possibility to prolong the survival of patients, and even obtain the chance of cure. The authors introduce the diagnosis and treatment of an advanced HCC patient with inter-ventional treatment combined with immunotherapy plus anti-angiogenesis targeted therapy. Results show that patient achieving pathological complete response and undergoing resection after conver-sion therapy. The patient has a good prognosis with a better quality of live.
